In Ovo is an Agricultural Technology (AgTech) company that aims to end the culling of male chicks in the value chain of the consumer egg industry. Based on unique and patented biomarker identification, the company has developed a commercially viable and scalable machine that is able to determine the sex of embryos in-egg, within days after fertilisation.
Rembrandt M&A acted as financial advisor to the shareholders of In Ovo in the series B equity raise from European Circular Bioeconomy Fund (ECBF), Evonik Venture Capital (Germany), VisVires New Protein (Singapore) and Demcon (Netherlands). The provided capital will be used to finance commercial machines, working capital and the international expansion strategy.
Rembrandt M&A
Advised in the sale of
In Ovo
to